Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Virios Therapeutics (Nasdaq: VIRI) announced that its Chairman and CEO, Greg Duncan, will be featured on The RedChip Money Report, airing on Bloomberg Network on April 17, 2021, at 7 p.m. Eastern Time. The company is focused on developing novel antiviral therapies for diseases linked to immune responses triggered by viruses. Their lead candidate, IMC-1, is a fixed-dose combination therapy targeting herpes simplex virus-1, showing promising results in Phase 2 trials for fibromyalgia and currently undergoing a Phase 2B trial. The FDA has granted IMC-1 fast track designation.
- Lead candidate IMC-1 shows promise for fibromyalgia, supported by Phase 2 trial results.
- IMC-1 has received fast track designation from the FDA, potentially accelerating its development.
- None.
Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today announced an interview with Chairman and CEO, Greg Duncan, will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, April 17, 2021 at 7 p.m. Eastern Time across the United States. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. Eastern Time in 73 million homes.
To view the interview segment, please visit: https://youtu.be/9M0B8RPahYs
“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
About Virios Therapeutics
Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2 clinical trial. These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia. IMC-1 has been granted fast track designation by the FDA and is currently being tested in a multi-center, randomized, double-blind, placebo-controlled Phase 2B trial (“FORTRESS”) designed to set the stage for registrational studies. The company is led by an executive team highly experienced in the successful development and commercialization of novel therapies. For more information, please visit www.virios.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. (VIRI) undertakes no duty to update such information except as required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210416005036/en/
FAQ
What is Virios Therapeutics focused on?
When will Greg Duncan's interview air on The RedChip Money Report?
What is the significance of IMC-1 for fibromyalgia?
Which regulatory designation has IMC-1 received?
What type of study is IMC-1 currently undergoing?
